Will the FDA approve any psychedelic substance for medical use this year? (Before 2027)
14%chance▼ 3
Install
FDA decision: Saroglitazar by Zydus Therapeutics (in 2026)
The odds
71%chance
How the odds have moved
Yes: 72% on Oct 19, 71% now.
Each outcome's chance over time on Kalshi. The dots along the bottom are headlines about its subject: point at one to read it.
Every outcome
| Outcome | Chance | Day | Bid | Ask | Pays | Contracts |
|---|---|---|---|---|---|---|
| Yes | 71% | 67¢ | 75¢ | $1.33 | 1.3K |
"Pays" is what a $1 stake returns if that outcome happens, at the price shown (before any fees). Bid and ask are the best prices to sell and buy "Yes".
The news: FDA, Zydus Therapeutics, Saroglitazar
Search ›-
The FDA says there’s no estrogen patch shortage. Women are struggling to fill prescriptions.Estrogen patches are the most commonly reported shortage in the U.S., but the FDA says it’s working to boost supply. Women across the country are still struggling to fill prescriptions for estrogen patches. -
MDMA-assisted therapy could get FDA approval as soon as January, top advocate predicts — but there’s a major problem loomingA drug once synonymous with rave culture could soon be making its way into a very different setting: the therapist’s office. A leading psychedelics advocate is “very optimistic” the Food and Drug Administration could approve MDMA-assisted… -
FDA issues recall over compounded GLP-1 weight loss drugsFox News contributor Dr. Stephanie Widmer discusses the recall of certain compounded GLP-1 medications over sterility concerns. FDA issues recall over compounded GLP-1 weight loss drugs Fox News contributor Dr. Stephanie Widmer discusses… -
FDA has finalized its guidance on apps related to drugsSTAT is a media company focused on finding and telling compelling stories about health, medicine, and scientific discovery. We produce daily news, investigative articles, and narrative projects in addition to multimedia features, podcasts… -
FDA Approves Subcutaneous Risankizumab Induction for Crohn’s DiseaseApproval rests on the phase 3 AFFIRM trial, in which 56% of patients reached clinical remission at week 12 vs 30% with placebo. The US Food and Drug Administration (FDA) approved a subcutaneous induction regimen of risankizumab-rzaa… -
FDA Launches New Accelerator for Alzheimer’s Disease PreventionDiscover how the FDA's new accelerator advances Alzheimer's disease prevention trials and delays dementia cognitive decline. Read more. This site is intended for healthcare professionals FDA Launches New Accelerator for Alzheimer’s Disease… -
FDA to pull common but ineffective cold medicine from marketNovember 7, 2024 / 12:32 PM EST / CBS News The Food and Drug Administration announced Wednesday that it would seek to pull a widely used ingredient in cough and cold medicines from the market, after the agency's scientists concluded that… -
Recent FDA Actions: Spring 2023In breast cancer, approval for elacestrant and a new indication for sacituzumab govitecan; approval for pirtobrutinib for mantle cell lymphoma. The primary end point in the study was PFS, and secondary end points included OS, overall… -
FDA approves once-weekly insulin icodec for pediatric T2DThe FDA approved insulin icodec-abae for children 10+ with T2D, based on adult ONWARDS data and a single-dose pediatric pharmacokinetic study. "Children with type 2 diabetes face an aggressive disease trajectory," said Eda Cengiz, MD, MHS… -
FDA Approved Agents for Lupus Nephritis: Belimumab and VoclosporinGerman Hernandez, MD, FASN, FACP, and Ellen Ginzler, MD, MPH, provide insight into the FDA approved therapies for lupus nephritis, belimumab and voclosporin, including an overview of clinical evidence, mechanism of action, and patient… -
Telehealth leapfrogs FDA approval with off-label GLP-1 prescriptions for addictionSTAT Telehealth leapfrogs FDA approval with off-label GLP-1 prescriptions for addiction Online platforms, experts say, can shift the burden of vetting unapproved drugs on to patients Katie covers the impact of health technology on… -
US FDA Looking To Modernize Clinical Trial Regulations To Spur ‘Evolution’ In ResearchPreviewing major regulatory, market access and political themes. The Center for Drug Evaluation and Research’s new Center for Clinical Trial Innovation (C3TI) may lead a “targeted” effort to update the FDA’s regulatory framework given…
Related markets
All fda & drugs ›Will the FDA approve retatrutide? (retatrutide (LY3437943))
Oct 22, 2027even chance by
- Before Jan 1, 20274%
- Before Jul 1, 202718%
- Before Jan 1, 202871%
2 more
- Before Jul 1, 202885%
- Before Jan 1, 202990%
When will the FDA reclassify BPC-157 to Category 1?
21%Before 2027
- Before 202721%
- Before November6%▼ 2
FDA decision: BBP-418 by Ml Bio Solutions Inc. (in 2026)
92%chance▲ 1
Will the FDA approve cytisinicline for smoking cessation?
39%Before Jul 1, 2027
- Before Jan 1, 202712%
- Before Jul 1, 202739%▲ 1
When will the FDA approve Compass Pathways' COMP360 Psilocybin? (COMP360 Psilocybin for Treatment-Resistant Depression)
88%Before 2028
- Before 202888%
- Before July 202785%
- Before October 202785%
2 more
- Before Mar 1, 202762%
- Before Jan 1, 202724%
Odds are traders' prices on Kalshi, Polymarket, ForecastEx and Crypto.com, not forecasts by 4Conservative. Prices read from the venues 4 min ago. Prices may be delayed. Money traded on Kalshi and ForecastEx is estimated from contracts. Not betting or investment advice.
Prediction-market prices are what traders pay for each outcome on Kalshi, Polymarket, ForecastEx and Crypto.com, read as the market's implied chance. They are not forecasts by 4Conservative, can move fast and can be wrong; they are read every few minutes and may be delayed. Money traded on Kalshi and ForecastEx is estimated from contracts at their price. News comes from the 4Conservative index; prices of stocks, rates and coins from 4Conservative Finance. Nothing here is betting, financial or investment advice. Terms of use. How to use Predictions